ITMI20010206A1 - Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz - Google Patents
Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz Download PDFInfo
- Publication number
- ITMI20010206A1 ITMI20010206A1 IT2001MI000206A ITMI20010206A ITMI20010206A1 IT MI20010206 A1 ITMI20010206 A1 IT MI20010206A1 IT 2001MI000206 A IT2001MI000206 A IT 2001MI000206A IT MI20010206 A ITMI20010206 A IT MI20010206A IT MI20010206 A1 ITMI20010206 A1 IT MI20010206A1
- Authority
- IT
- Italy
- Prior art keywords
- prevention
- treatment
- hours
- kidney
- ischemia
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 12
- 230000002265 prevention Effects 0.000 title claims description 9
- 231100000252 nontoxic Toxicity 0.000 title claims description 8
- 230000003000 nontoxic effect Effects 0.000 title claims description 8
- 239000003814 drug Substances 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title claims description 6
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 title claims description 4
- 229940079593 drug Drugs 0.000 title description 3
- 210000003734 kidney Anatomy 0.000 claims description 35
- 208000028867 ischemia Diseases 0.000 claims description 21
- 230000000302 ischemic effect Effects 0.000 claims description 14
- 230000006378 damage Effects 0.000 claims description 12
- 210000000056 organ Anatomy 0.000 claims description 11
- 206010063837 Reperfusion injury Diseases 0.000 claims description 10
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 9
- URZONQSEPBBTSB-HNCPQSOCSA-N methanesulfonamide;(2r)-2-[4-(2-methylpropyl)phenyl]propanoic acid Chemical compound CS(N)(=O)=O.CC(C)CC1=CC=C([C@@H](C)C(O)=O)C=C1 URZONQSEPBBTSB-HNCPQSOCSA-N 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical class NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 230000010410 reperfusion Effects 0.000 claims description 5
- HEFNNWSXXWATRW-SNVBAGLBSA-N levibuprofen Chemical compound CC(C)CC1=CC=C([C@@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-SNVBAGLBSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 235000019766 L-Lysine Nutrition 0.000 claims description 2
- 150000008545 L-lysines Chemical class 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 18
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
- 102000004890 Interleukin-8 Human genes 0.000 description 11
- 108090001007 Interleukin-8 Proteins 0.000 description 11
- 229940096397 interleukin-8 Drugs 0.000 description 11
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 11
- 238000002054 transplantation Methods 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 208000037906 ischaemic injury Diseases 0.000 description 7
- 230000003907 kidney function Effects 0.000 description 7
- 229940109239 creatinine Drugs 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000000626 ureter Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- -1 IL- 10 Proteins 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003872 anastomosis Effects 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000001434 glomerular Effects 0.000 description 2
- 238000011694 lewis rat Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 210000002254 renal artery Anatomy 0.000 description 2
- 210000002796 renal vein Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 208000021709 Delayed Graft Function Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101150057615 Syn gene Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000030505 negative regulation of chemotaxis Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000082 organ preservation Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Priority Applications (27)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001MI000206A ITMI20010206A1 (it) | 2001-02-02 | 2001-02-02 | Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz |
| BRPI0206804A BRPI0206804B1 (pt) | 2001-02-02 | 2002-01-30 | utilização de (r)-ibuprofeno metanossulfonamida e sais do mesmo no tratamento e prevenção de lesão funcional resultante de reações de rejeição de orgãos transplantados |
| EEP200300340A EE05233B1 (et) | 2001-02-02 | 2002-01-30 | (R)-ibuprofeenmetaansulfoonamiidi v?i selle soola kasutamine ravimite valmistamiseks, mis on ette nhtud siiratud elundite isheemia/reperfusiooni kahjustuse rahoidmiseks v?i raviks |
| MXPA03006686A MXPA03006686A (es) | 2001-02-02 | 2002-01-30 | Uso de metanosulfonamida de ( r ) ibuprofen y sales de la misma en el tratamiento y prevencion de las reacciones de rechazo de organos transplantados. |
| SK973-2003A SK287632B6 (sk) | 2001-02-02 | 2002-01-30 | Použitie (R)-ibuprofénmetánsulfonamidu alebo jeho solí |
| JP2002562337A JP2004517948A (ja) | 2001-02-02 | 2002-01-30 | 移植器官の拒絶反応の治療および予防における（ｒ）−イブプロフェンメタンスルホンアミドおよびその塩の使用 |
| CZ20032095A CZ303665B6 (cs) | 2001-02-02 | 2002-01-30 | Farmaceutický prostredek |
| HU0303024A HU229070B1 (hu) | 2001-02-02 | 2002-01-30 | (R)-ibuprofen-metánszulfonamid és sói alkalmazása kilökõdési reakciók kezelésére és megelõzésére alkalmas gyógyászati készítmény elõállítására |
| AU2002250869A AU2002250869B2 (en) | 2001-02-02 | 2002-01-30 | Use of (R)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs |
| PT02719742T PT1355641E (pt) | 2001-02-02 | 2002-01-30 | Utilizacao de (r)-ibuprofen-metanossulfonamida e os seus sais no tratamento e prevencao das reaccoes de rejeicao de orgaos transplantados |
| CA002432432A CA2432432C (en) | 2001-02-02 | 2002-01-30 | Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs |
| PCT/EP2002/000946 WO2002062330A2 (en) | 2001-02-02 | 2002-01-30 | Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs |
| PL363576A PL215109B1 (pl) | 2001-02-02 | 2002-01-30 | Zastosowanie (R)-ibuprofeno-metanosulfonamidu i jego nietoksycznych soli do wytwarzania leków |
| EP02719742A EP1355641B1 (en) | 2001-02-02 | 2002-01-30 | Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs |
| DK02719742T DK1355641T3 (da) | 2001-02-02 | 2002-01-30 | Anvendelse af (R)-ibuprofen-methansulfonamid og salte deraf ved behandling og forebyggelse af afstödningsreaktioner i transplanterede organer |
| NZ526655A NZ526655A (en) | 2001-02-02 | 2002-01-30 | Use of (R)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs |
| AT02719742T ATE304846T1 (de) | 2001-02-02 | 2002-01-30 | Verwendung von r-ibuprofen methanesulfonamied und dessen salzen zur behandlung und verhinderung von abstossungreaktionen in transplartierten organen |
| KR1020037009714A KR100857898B1 (ko) | 2001-02-02 | 2002-01-30 | 이식된 장기의 거부반응의 치료와 예방에 사용되는(ｒ)-이부프로펜 메탄설폰아마이드 및 이의 염 |
| CNA028042263A CN1561205A (zh) | 2001-02-02 | 2002-01-30 | (r)－异丁苯丙酸甲基磺酰胺及其盐在治疗和预防移植器官排斥反应中的应用 |
| DE60206245T DE60206245T2 (de) | 2001-02-02 | 2002-01-30 | Verwendung von r-ibuprofen methanesulfonamid und dessen salzen zur behandlung und verhinderung von abstossungsreaktionen in transplantierten organen |
| ES02719742T ES2248541T3 (es) | 2001-02-02 | 2002-01-30 | Uso de (r)-iboprufen metanosulfonamida y sales del mismo en el tratamiento y prevencion de las reacciones de rechazo de organos transplantad0s. |
| BR0206804-4A BR0206804A (pt) | 2001-02-02 | 2002-01-30 | Utilização de (r)-ibuprofeno metanossulfonamida e sais do mesmo no tratamento e prevenção de reações de rejeição a órgãos transplantados |
| RU2003126600/15A RU2257895C2 (ru) | 2001-02-02 | 2002-01-30 | Применение (r)-ибупрофенметансульфонамида и его солей для лечения и предотвращения реакций отторжения трансплантируемых органов |
| US10/250,465 US7560487B2 (en) | 2001-02-02 | 2003-01-30 | Use of (R)—ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs |
| ZA200304861A ZA200304861B (en) | 2001-02-02 | 2003-06-23 | The use of (R)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs. |
| NO20033273A NO334285B1 (no) | 2001-02-02 | 2003-07-18 | Anvendelse av (R)-ibuprofen-metansulfonamid og salter derav til behandling og forhindring av avstøtning av transplanterte organer |
| IL157180A IL157180A (en) | 2001-02-02 | 2003-07-31 | Use of (R) - ibupropane methanesulfonamide and its salts for the preparation of drugs for the treatment and prevention of rejection reactions of transplanted organs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001MI000206A ITMI20010206A1 (it) | 2001-02-02 | 2001-02-02 | Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ITMI20010206A1 true ITMI20010206A1 (it) | 2002-08-02 |
Family
ID=11446717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT2001MI000206A ITMI20010206A1 (it) | 2001-02-02 | 2001-02-02 | Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7560487B2 (https=) |
| EP (1) | EP1355641B1 (https=) |
| JP (1) | JP2004517948A (https=) |
| KR (1) | KR100857898B1 (https=) |
| CN (1) | CN1561205A (https=) |
| AT (1) | ATE304846T1 (https=) |
| AU (1) | AU2002250869B2 (https=) |
| BR (2) | BR0206804A (https=) |
| CA (1) | CA2432432C (https=) |
| CZ (1) | CZ303665B6 (https=) |
| DE (1) | DE60206245T2 (https=) |
| DK (1) | DK1355641T3 (https=) |
| EE (1) | EE05233B1 (https=) |
| ES (1) | ES2248541T3 (https=) |
| HU (1) | HU229070B1 (https=) |
| IL (1) | IL157180A (https=) |
| IT (1) | ITMI20010206A1 (https=) |
| MX (1) | MXPA03006686A (https=) |
| NO (1) | NO334285B1 (https=) |
| NZ (1) | NZ526655A (https=) |
| PL (1) | PL215109B1 (https=) |
| PT (1) | PT1355641E (https=) |
| RU (1) | RU2257895C2 (https=) |
| SK (1) | SK287632B6 (https=) |
| WO (1) | WO2002062330A2 (https=) |
| ZA (1) | ZA200304861B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1579859E (pt) * | 2004-03-25 | 2007-03-30 | Dompe Pha R Ma Spa Res & Mfg | Utilização de n-(2-aril-propionil)-sulfonamidas pata o tratamento de lesões da medula espinal |
| EP1883405A4 (en) | 2005-05-09 | 2010-01-27 | Takeda Pharmaceuticals North A | METHODS OF TREATING NEPHROLITHIASIS |
| KR20150024919A (ko) * | 2006-11-13 | 2015-03-09 | 다케다 파마슈티칼스 유에스에이, 인코포레이티드 | 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법 |
| EP2308484A1 (en) * | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets |
| EP2308485A1 (en) * | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Sulfonamides for the prevention of diabetes |
| CA2812034C (en) | 2010-09-10 | 2018-10-23 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for concomitant treatment of theophylline and febuxostat |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| US10561676B2 (en) * | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
| US20200003787A1 (en) * | 2017-03-15 | 2020-01-02 | Numares Ag | Method for Using a Marker Set for Determining the Risk of Kidney Rejection |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879283A (en) * | 1985-10-03 | 1989-11-07 | Wisconsin Alumni Research Foundation | Solution for the preservation of organs |
| RU2008901C1 (ru) * | 1991-03-29 | 1994-03-15 | Донецкий государственный медицинский институт им.М.Горького | Способ фармакологической защиты децентрализованной почки |
| RU2126262C1 (ru) * | 1992-09-17 | 1999-02-20 | Амген Боулдер Инк. | Фармацевтическая композиция |
| IL110296A (en) * | 1993-07-16 | 1999-12-31 | Smithkline Beecham Corp | Imidazole compounds process for their preparation and pharmaceutical compositions containing them |
| JPH08231413A (ja) * | 1994-12-29 | 1996-09-10 | Mochida Pharmaceut Co Ltd | 臓器障害に基づく疾患の予防・治療剤 |
| IT1303249B1 (it) * | 1998-10-23 | 2000-11-06 | Dompe Spa | Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono. |
| US6355682B1 (en) * | 2001-05-11 | 2002-03-12 | Assa Weinberg | Treatment of acute renal failure by administration of N-acetylcysteine |
-
2001
- 2001-02-02 IT IT2001MI000206A patent/ITMI20010206A1/it unknown
-
2002
- 2002-01-30 EP EP02719742A patent/EP1355641B1/en not_active Expired - Lifetime
- 2002-01-30 CZ CZ20032095A patent/CZ303665B6/cs not_active IP Right Cessation
- 2002-01-30 RU RU2003126600/15A patent/RU2257895C2/ru not_active IP Right Cessation
- 2002-01-30 MX MXPA03006686A patent/MXPA03006686A/es active IP Right Grant
- 2002-01-30 AU AU2002250869A patent/AU2002250869B2/en not_active Ceased
- 2002-01-30 AT AT02719742T patent/ATE304846T1/de active
- 2002-01-30 PT PT02719742T patent/PT1355641E/pt unknown
- 2002-01-30 BR BR0206804-4A patent/BR0206804A/pt not_active IP Right Cessation
- 2002-01-30 CA CA002432432A patent/CA2432432C/en not_active Expired - Fee Related
- 2002-01-30 CN CNA028042263A patent/CN1561205A/zh active Pending
- 2002-01-30 EE EEP200300340A patent/EE05233B1/xx not_active IP Right Cessation
- 2002-01-30 JP JP2002562337A patent/JP2004517948A/ja active Pending
- 2002-01-30 KR KR1020037009714A patent/KR100857898B1/ko not_active Expired - Fee Related
- 2002-01-30 PL PL363576A patent/PL215109B1/pl unknown
- 2002-01-30 ES ES02719742T patent/ES2248541T3/es not_active Expired - Lifetime
- 2002-01-30 HU HU0303024A patent/HU229070B1/hu not_active IP Right Cessation
- 2002-01-30 SK SK973-2003A patent/SK287632B6/sk not_active IP Right Cessation
- 2002-01-30 DK DK02719742T patent/DK1355641T3/da active
- 2002-01-30 WO PCT/EP2002/000946 patent/WO2002062330A2/en not_active Ceased
- 2002-01-30 DE DE60206245T patent/DE60206245T2/de not_active Expired - Lifetime
- 2002-01-30 NZ NZ526655A patent/NZ526655A/en not_active IP Right Cessation
- 2002-01-30 BR BRPI0206804A patent/BRPI0206804B1/pt unknown
-
2003
- 2003-01-30 US US10/250,465 patent/US7560487B2/en not_active Expired - Fee Related
- 2003-06-23 ZA ZA200304861A patent/ZA200304861B/en unknown
- 2003-07-18 NO NO20033273A patent/NO334285B1/no not_active IP Right Cessation
- 2003-07-31 IL IL157180A patent/IL157180A/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ITMI20010206A1 (it) | Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz | |
| AU2002250869A1 (en) | Use of (R)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs | |
| Balsam et al. | Early inhibition of caspase-3 activity lessens the development of graft coronary artery disease | |
| Ueda et al. | AGE-ASSOCIATED INCREASE IN OXIDATIVE DAMAGE AND DOWN-REGULATION OF EXTRACELLULAR SUPEROXIDE DISMUTASE (EC-SOD) IN ENDOTOXINMEDIATED ACUTE LUNG INJURY | |
| Edelman et al. | Post-traumatic hypotension: Should systolic blood pressure of 90-109 mmhg be included? | |
| McMullin et al. | Recombinant human factor VIIa (rhFVIIa) reduces rebleed hemorrhage volume in swine aortotomy model. | |
| Miao et al. | INHIBITION OF ENTERAL ENZYME WITH FUTHAN REDUCES MESENTERIC LYMPH-INDUCED ENDOTHELIAL CELL DEATH | |
| Woolsey et al. | AGED MICE HAVE ALTERED CYTOKINE PROFILES AND INTESTINAL PERMEABILITY FOLLOWING CECAL LIGATION AND PUNCTURE | |
| Scott et al. | LIPOPOLYSACCHARIDE (LPS) UPTAKE INTO LIVER HEPATOCYTES (HC) IN VIVO IS CD14-DEPENDENT | |
| Chen et al. | THE ROLE OF MYD88-INDEPENDENT, TRIF PATHWAY IN POLYMICROBIAL SEPSIS | |
| Maitra et al. | p38 MAPK REGULATES MMP-9 RELEASE IN LIVER OF SEPTIC RATS AND TRANSFECTED RAW 264.7 CELLS | |
| Zenker et al. | Continuous sublingual PCO2 as a rapid indicator of changes in tissue perfusion in hemorrhagic shock: an experimental study | |
| Swan et al. | SEPSIS DIFFERENTIALLY AFFECTS MACROPHAGE (MØ) CLEARANCE OF APOPTOTIC THYMOCYTES | |
| Norris et al. | Multiple heart rate variabilty measurements reflect mortality in 2,438 trauma patients. | |
| Nakano et al. | THERAPEUTIC APPROACH FOR SEPSIS FOLLOWING SMOKE INHALATION AND PNEUMONIA | |
| Yang et al. | HEMORRHAGIC SHOCK IN THE RAT: COMPARISON OF FEMORAL AND CAROTID TECHNIQUES | |
| Lim et al. | INTER-ALPHA INHIBITORS IN ADULT AND NEONATAL SEPSIS: A POTENTIAL APPLICATION AS AN INTEGRATED CLINICAL MARKER AND THERAPEUTIC AGENT | |
| Stephens et al. | The effects of norepinephrine (NE) and dobutamine (DE) on blood volume expansion. | |
| Maass et al. | THE ROLE OF CASPASES IN MYOCARDIAL INFLAMMATION AFTER BURN INJURY. | |
| Varma et al. | LPS-tolerance improves survival and bacterial clearance in mice with burn wound infections. | |
| Wang et al. | Activation of liver x receptor by synthetic agonist t0901317 reduces the liver injury caused by lipopolysaccharide in the rat: A novel principle for treatment of sepsis and shock | |
| Batchelder et al. | RESPONSE OF FIVE INBRED MOUSE STRAINS TO POLYMICROBIAL SEPSIS | |
| Rivera-Chavez et al. | A TREM-1 polymorphism influences mortality and sepsis severity in burn patients. | |
| Schwulst et al. | FADD-DN AND BID−/− MICE HAVE PROTECTION AGAINST LYMPHOCYTE APOPTOSIS AND IMPROVED SURVIVAL IN SEPTIC PERITONITIS | |
| Al-Ghoul et al. | Simvastatin attenuates postburn intestinal tissue damage in rats. |